Filtered by Topic
Latest Pharmaceuticals news and updates from Switzerland. AI-curated articles covering Pharmaceuticals topics.
← Show All NewsPharmaceuticals
Novartis and Roche are among the few major pharmaceutical companies still investing in access to medicines for poorer countries, a new index finds. The report warns that geopolitical tensions and pressure to focus on wealthy markets could undermine progress for patients in low- and middle-income countries.
2 days ago · 1 source
Health
Novartis says it has received reports of nine cases of tumours in children treated with its gene therapy Zolgensma. In two cases, investigators found genetic material from the therapy’s delivery vehicle in the patients’ DNA.
SWI swissinfo.ch
Business
Lonza is acquiring five US manufacturing sites from Germany’s Merck Group, doubling its US network of contract development and manufacturing sites from four to nine. Around 1,100 employees are expected to transfer to the Swiss life sciences group.
SWI swissinfo.ch
Healthcare
A study by ETH Zurich and the University of Zurich warns that US pressure to lower medicine prices could lead pharmaceutical companies to seek higher prices elsewhere. If Switzerland accepts those increases, households could face hundreds of millions of francs in additional annual costs.
SWI swissinfo.ch
Business
Spanish pharmaceutical group STE Pharmaceuticals plans to convert a former factory in Couvet, Neuchâtel, into a 15,000-square-metre production and research site by 2032. The company says the expansion is intended to create skilled jobs, although it has not yet estimated how many.
SWI swissinfo.ch
Switzerland
Roche reported sales of CHF46.5 billion for the first nine months of 2026, up 6% at constant exchange rates, and maintained its full-year targets. A weaker Swiss franc provided some relief from currency headwinds in the third quarter.
SWI swissinfo.ch
Business
Roche has agreed to pay $510 million for rights to a portfolio of antibody-drug conjugates developed by China’s Hansoh Pharma. Hansoh will lead early development, with Roche set to take over global development after the first clinical phase, subject to regional exceptions.
SWI swissinfo.ch
Business
Roche is paying $510 million for global rights to a portfolio of antibody-drug conjugates developed by China’s Hansoh Pharma. The cancer treatments combine antibodies with chemotherapy molecules, with Roche taking over development after the first clinical phase.
SWI swissinfo.ch
Switzerland
The first successful Phase III trial of a personalised mRNA cancer vaccine has renewed hopes for treatments tailored to individual tumours. Swiss researchers and pharmaceutical companies are assessing whether the country can compete in the rapidly advancing field.
SWI swissinfo.ch
Switzerland
Roche has reported positive 52-week results for vamikibart, an experimental treatment for vision loss linked to uveitis. The drug improved vision and reduced retinal swelling in two Phase III trials, but has not yet been approved.
SWI swissinfo.ch
Roche
Roche says its experimental once-weekly obesity treatment reduced body weight by an average 15.5% after 48 weeks in overweight or obese people with type 2 diabetes. Analysts called the mid-stage results competitive but stressed that larger Phase 3 trials are still needed.
SWI swissinfo.ch
Business
Roche has opened a major research and development centre in Boston focused on cardiovascular, renal and metabolic diseases, expanding its US research footprint with space for up to 500 specialists.
SWI swissinfo.ch
Switzerland
An industry-backed study warns that changes in US pharmaceutical policy could cost Switzerland almost CHF95 billion by 2040 through weaker growth and possible relocation of production.
SWI swissinfo.ch
Business
The Australian pharmaceutical group CSL Behring has completed a transformation process at its Bern site, resulting in a reduction of its workforce by just under 10%. The company stated the move strengthens its long-term competitiveness.
SWI swissinfo.ch
Healthcare
A new report revealing that drug discounts are not being passed on to consumers has sparked political outrage, highlighting a system where Swiss patients struggle to access innovative medicines.
The Local Switzerland · +2 more
Business
Pharmaceutical giant Sandoz has signed a multi-million-dollar agreement with Shanghai Henlius Biotech to develop and commercialize up to ten biosimilars, significantly expanding its footprint in the generic biologics market.
SWI swissinfo.ch
Business
While Basel's world-beating pharmaceutical hub adapts to a new global order, major Swiss firms like Roche and Novartis are aggressively expanding their footprint in the United States, particularly North Carolina, signaling a strategic shift to secure future growth.
SWI swissinfo.ch · +1 more
Sandoz
Basel-based pharmaceutical firm Sandoz has agreed to a settlement of nearly $480 million in a long-running US antitrust lawsuit. The case, involving 43 states, alleged unlawful price-fixing in the generics market, though Sandoz does not admit guilt in the settlement.
SWI swissinfo.ch
Business
Swiss pharmaceutical firm Sandoz has received marketing authorization in Brazil for a generic version of the popular GLP-1 drug semaglutide. The move marks a significant expansion for the Basel-based company into the lucrative $1.8 billion Brazilian market for diabetes treatments.
SWI swissinfo.ch
Business
Swiss pharmaceutical giant Novartis has announced the acquisition of British start-up Myricx Bio for an initial $1.1 billion, a strategic move to bolster its portfolio of antibody-drug conjugates for treating various solid tumours.
SWI swissinfo.ch
